公司资料
Alnylam Pharmaceuticals, Inc. 股价、新闻与催化剂
- 股票代码:
- ALNY
- 交易所:
- NASDAQ
- 行业:
- Nucleic Acid Drugs
- 所在地:
- Cambridge, Massachusetts
股票表现
231.18 USD (-6.31%)
收盘价
最后更新: 2026年10月1日
38.2B USD
市值
股价为何变动
截至 2026年10月1日，ALNY 下跌 6.31%，收于 $231.18。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
RNA Interference Therapeutics Leader
Alnylam Pharmaceuticals develops medicines that use RNA interference to silence disease-causing genes. Its platform is designed to achieve durable reduction of specific proteins through infrequent subcutaneous or intravenous dosing, with programs spanning rare, cardiometabolic, and neurological diseases.
Transthyretin Amyloidosis Franchise
The company's largest franchise is built around AMVUTTRA and ONPATTRO for transthyretin-mediated amyloidosis. AMVUTTRA is positioned across both polyneuropathy and cardiomyopathy manifestations of ATTR, giving Alnylam a broad commercial presence in a progressive systemic disease.
Commercial Rare-Disease Portfolio
Alnylam also markets GIVLAARI for acute hepatic porphyria and OXLUMO for primary hyperoxaluria type 1. These products demonstrate the platform's ability to address liver-expressed genetic targets and support a specialized commercial model centered on diagnosis, patient identification, and long-term treatment.
Partnered Medicines and Economics
The company receives royalties from partnered RNAi medicines, including Leqvio, and collaborates with large pharmaceutical companies on development programs such as zilebesiran for hypertension. This structure allows Alnylam to retain selected products while using partners to reach broader primary-care and global markets.
Expanding Pipeline Beyond the Liver
Pipeline programs include ALN-6400 for bleeding disorders, mivelsiran for neurological disease, ALN-HTT02 for Huntington's disease, and ALN-2232 for obesity and weight management. New delivery approaches are intended to extend RNAi into the central nervous system and other tissues beyond the liver.
未来催化剂
- Presentation of Phase 1 ALN-HTT02 data in Huntington's disease at the 2026 European Huntington's Disease Network meeting.
- Phase 1 clinical results for ALN-6400 in healthy volunteers during 2026.
- Phase 1 clinical results for ALN-2232 in obesity and weight management during 2026.
近期新闻
新闻标题由机器翻译，详情为英文原文。
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。